 A population based study in Germany identified more than 300 cases of osteonecrosis of the jaw, 97% occurring in cancer patients (on high-dose intravenous bisphosphonates) and 3 cases in 780,000 patients with osteoporosis for an incidence of 0.00038%.Time to event ranged from 23–39 months and 42–46 months with high dose intravenous and oral bisphosphonates.A prospective, population based study by Mavrokokki "et al.